# Aphelion Capital

> Aphelion Capital is a VC fund backing Health Care and Medical Device. See 41 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Mill Valley, United States
- Total investments: 41
- Last investment: Mar 2025
- Lead investor: 20%
- Fund size: $45M
- Last fund: Jul 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/aphelion-capital
- X (Twitter): https://twitter.com/aphelioncapital
- Website: http://www.aphelioncapital.net

Aphelion Capital is a venture capital firm focused on supporting the growth of innovative medical technology with an emphasis on fast to market, low capital intense products that reduce the cost of delivering quality healthcare. They leverage their considerable knowledge and deep networks to accelerate commercial success of a company. Theirteam has extensive experience investing in healthcare companies across both the private and public equity markets.

## Contacts

5 contacts available for Aphelion Capital. Shizune tracks 4 team members at Aphelion Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/aphelion-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 23 | 56% |
| Medical Device | 18 | 44% |
| Medical | 13 | 32% |
| Biotechnology | 10 | 24% |
| Software | 3 | 7% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 22% |
| Series B | 8 | 20% |
| Series C | 8 | 20% |
| Series D | 6 | 15% |
| Seed | 2 | 5% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 24 | 59% |
| Canada | 1 | 2% |
| United Kingdom | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Edwin Scheetz | Founder & Managing Partner | 11 | https://shizune.co/investors/profile/ned-scheetz |
| John Kim | Principle | 1 | https://shizune.co/investors/profile/john-hyung |
| Robert W. Thomas | Venture Partner | 0 | https://shizune.co/investors/profile/robert-w-thomas |
| Kris Johnson | President | 0 | https://shizune.co/investors/profile/kris-johnson |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M | Series C | Mar 19, 2025 |  |
| Laplace Interventional | Laplace developing Transcatheter Tricuspid Valve Technology to offer an increase in life expectancy and an improvement to the quality of life to worldwide patients with tricuspid regurgitation. | $22M | Series C | Mar 16, 2025 |  |
| Venova Medical | Venova Medical develops vascular access systems for patients requiring renal replacement therapy. It addresses patient level and system barriers for access creation while simultaneously providing quickly functioning access with less need for intervention. The company was founded in 2018 and is headquartered in Los Gatos, California. | $30M | Series B | Sep 04, 2024 |  |
| Nectero Medical | Nectero Medical develops a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms. The company was founded in 2017 and is headquartered in Dover, Delaware, United States. | $96M | Series D | Apr 11, 2024 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M | Venture - Series Unknown | Apr 04, 2024 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M | Series D | Apr 04, 2024 |  |
| Phagenesis | Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology. | $42M | Series D | Mar 04, 2024 |  |
| Moving Analytics | Moving Analytics is a telehealth service provider that specializes in cardiovascular prevention programs. Its first product Movn is an end-to-end, integrated program to deliver remote and virtual cardiac rehab. The platform reduces readmissions and empowers the effective and efficient delivery of quality care to patients based on 30+ years ofresearch in remote disease management from Stanford University. | $20M | Series A | Jul 08, 2022 |  |
| Elucid | Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from asingle CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services. | $27M | Series B | Jun 22, 2022 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M | Series B | Nov 02, 2021 |  |

10 of 41 investments shown.

## Co-investors
- [California Technology Ventures](https://shizune.co/investors/profile/california-technology-ventures) — VC Fund, 6 deals together
- [Features Capital](https://shizune.co/investors/profile/features-capital) — VC Fund, 4 deals together
- [RC Capital](https://shizune.co/investors/profile/river-cities-capital) — VC Fund, 4 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 4 deals together
- [Medvest Capital](https://shizune.co/investors/profile/stanmore-medical-investments) — VC Fund, 4 deals together
- [Taisho Pharmaceutical Holdings](https://shizune.co/investors/profile/taisho-pharmaceutical-holdings) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Aphelion Capital invest in?

Aphelion Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 41 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Aphelion Capital?

Public channels for Aphelion Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Aphelion Capital?

The team at Aphelion Capital includes Edwin Scheetz (Founder & Managing Partner), John Kim (Principle) and Robert W. Thomas (Venture Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co